Aplastic Anemia in a Patient with Cronkhite-Canada Syndrome

Kidoguchi, Keisuke; Kubota, Yasushi; Fujimoto, S.; Sakata, Yasuhisa; Kizuka-Sano, Haruna; Yamaguchi, Kyosuke; Ureshino, Hiroshi; Katsuya, Hiroo; Ando, Toshihiko; Esaki, Motohiro; Kimura, Shinya

doi:10.2169/internalmedicine.6468-20

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The etiology and pathogenesis of CCS are still unclear, but it involves genetic abnormalities, abnormal proliferation and differentiation of intestinal epithelial cells, immune system abnormalities and stress. [ 10 ] At present, it is generally considered to be a chronic inflammatory disease associated with autoimmune mechanisms, and the current evidence mainly includes ANA positivity, [ 11 ] the level of IgG4 in the blood circulation was increased, [ 12 ] polyps infiltrated with IgG4-positive plasma cells, [ 13 ] and an overall good clinical response to immunosuppressive therapy. [ 2 ] In addition.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive treatment of Cronkhite-Canada syndrome: A case report and literature review

Hu¹,

Wu²,

Zhang

et al. 2023

Medicine

View full text Add to dashboard Cite

Introduction: Cronkhite-Canada syndrome (CCS) is currently considered to be a non-hereditary disease, which is relatively rare clinically. It is also known as polyposis hyperpigmentation alopecia nail dystrophy syndrome, it is a syndrome characterized by gastrointestinal polyposis and ectodermal changes, the main manifestations are gastrointestinal symptoms, skin pigmentation, alopecia, and hypothyroidism. Case presentation: In this paper, the clinical characteristics, diagnosis and treatment of a case of CCS admitted to Huanghe Sanmenxia Hospital were analyzed. In the course of treatment, traditional Chinese medicine was used, but no hormone, and the patient’s clinical symptoms were greatly relieved. Conclusions: CCS is rare, there is no specific treatment, and traditional Chinese medicine may can greatly relieve the clinical symptoms of patients. However, it’s still having to be verified by a large sample, multi-center, long-term treatment follow-up studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive treatment of Cronkhite-Canada syndrome: A case report and literature review

Hu¹,

Wu²,

Zhang

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…CCS is generally considered to be a chronic inflammatory disease associated with autoimmune mechanisms. There is currently significant evidence including ANA-positive, elevated IgG4 levels in blood circulation, polyps infiltrating IgG4-positive plasma cells, and clinically good response to immunosuppressive therapy[ 3 - 5 ]. Currently, there are no internationally recognized diagnostic criteria or systematic treatments.…”

Section: Introductionmentioning

confidence: 99%

CronkhiteCanada syndrome complicated with pulmonary embolism: A case report

He,

Zheng,

Tian

2024

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Cronkhite-Canada syndrome (CCS) is a rare disease, that causes gastrointestinal polyps, ectodermal abnormalities, and gastrointestinal symptoms. CCS is prone to thromboembolism, but clinical workers have not yet established a clinical consciousness of preventing thromboembolism. The present case illustrates pulmonary embolism (PE) complicated by CCS. CASE SUMMARY A 46-year-old male patient presented with mucus, purulent, and bloody stool. Ectodermal changes included skin pigmentation, alopecia, and nail dystrophy. Colonoscopy revealed the presence of multiple polyps. After a comprehensive evaluation, the patient was diagnosed with CCS. During the disease, he was also diagnosed with pulmonary embolism, Riehl's melanosis, and intestinal flora imbalance. After symptomatic treatment with omeprazole, mesalazine, rivaroxaban, nutritional support, and regulation of intestinal flora, the patient’s symptoms were significantly relieved. CONCLUSION CCS complicated with PE was reported for the first time in China in this study. Despite the fact that CCS is extremely rare, patients with CCS should be classified as a high-risk venous thromboembolism (VTE) population, and emphasis should be placed on venous thromboembolism risk assessment and stratification, deep venous thromboembolism screening, prevention of VTE, and careful long-term follow-up.

show abstract

Mesalazine

2021

Reactions Weekly

View full text Add to dashboard Cite

Aplastic Anemia in a Patient with Cronkhite-Canada Syndrome

Cited by 4 publications

References 33 publications

Comprehensive treatment of Cronkhite-Canada syndrome: A case report and literature review

Comprehensive treatment of Cronkhite-Canada syndrome: A case report and literature review

CronkhiteCanada syndrome complicated with pulmonary embolism: A case report

Mesalazine

Contact Info

Product

Resources

About